STL Index for: Alexander Robbins

Deuruxolitinib (FDA-approved July 2024) is an oral JAK1/JAK2 inhibitor for severe alopecia areata. Learn about its mechanism, THRIVE-AA trial results showing rapid hair regrowth, safety profile, and how it compares to baricitinib and ritlecitinib.